No retraction, correction or concern found when last checked on Oct 23, 2026.

Dietary Compounds as Epigenetic Modulating Agents in Cancer

Ángeles Carlos-Reyes, José Sullivan López-González, Manuel Meneses-Flores and 6 more

Frontiers in Genetics · 2019 · Review · CC BY

doi:10.3389/fgene.2019.00079

Abstract

Epigenetic mechanisms control gene expression during normal development and their aberrant regulation may lead to human diseases including cancer. Natural phytochemicals can largely modulate mammalian epigenome through regulation of mechanisms and proteins responsible for chromatin remodeling. Phytochemicals are mainly contained in fruits, seeds, and vegetables as well as in foods supplements. These compounds act as powerful cellular antioxidants and anti-carcinogens agents. Several dietary compounds such as catechins, curcumin, genistein, quercetin and resveratrol, among others, exhibit potent anti-tumor activities through the reversion of epigenetic alterations associated to oncogenes activation and inactivation of tumor suppressor genes. In this review, we summarized the actual knowledge about the role of dietary phytochemicals in the restoration of aberrant epigenetic alterations found in cancer cells with a particular focus on DNA methylation and histone modifications. Furthermore, we discussed the mechanisms by which these natural compounds modulate gene expression at epigenetic level and described their molecular targets in diverse types of cancer. Modulation of epigenetic activities by phytochemicals will allow the discovery of novel biomarkers for cancer prevention, and highlights its potential as an alternative therapeutic approach in cancer.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1The knowledge of epigenetic mechanisms regulating gene expression has allowed significant advances in the understanding of cancer biology. Cancer is caused by the accumulation of genetic and epigenetic alterations, which induce alterations in the expression of oncogenes and tumor suppressor genes. Changes in the DNA sequence are caused by mutations, amplifications or deletions. Moreover, regulation of gene expression is also modulated by epigenetics modifications of chromatin with no alterations in DNA sequence. The main epigenetic mechanisms studied in mammalian cells are DNA methylation and histones modifications which induce remodeling of chromatin resulting in changes of cellular phenotypes. In cancer cells, diverse epigenetic alterations of cancer-related genes occur in the early stages of tumor development. Remarkably, these epigenetic modifications of chromatin are inherited and reversible, so they represent promising targets for the development of novel drugs targeting the epigenome which may contribute to amelioration of conventional therapies in cancer. Improvement in patient’s survival is the result of the use new therapeutic drugs and personalized options. Some of these treatments have been combined with alternative therapies represented by natural phytochemical compounds. It has been reported that a diet rich in vegetables and fruits can significantly reduce the risk of cancer development, due to the action of phytochemicals which may regulate the expression of oncogenes and tumor suppressor genes. Remarkably, phytochemicals may act through epigenetic mechanisms such as modulation of DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) activities. In general, cancer treatments involve the use of chemo-radio therapeutic agents, kinase inhibitors, personalized antibodies as well as compounds that stimulate the immune system. In particular, HDAC inhibitors and demethylating drugs modified gene expressions by reversing the aberrant epigenetic alterations acquired during tumorigenesis. In this context, phytochemicals may represent an alternative therapeutic option for cancer treatment. In this review, we first provided an overview of the most frequent epigenetic alterations in human cancers, then we described the most studied dietary phytochemicals and their potential use in the reversion of cancer hallmarks through epigenetic mechanisms, and finally we discussed their potential use as an alternative strategy for cancer therapy.

DNA Methylation

2DNA methylation is a normal mechanism of gene silencing by transcriptional repression. Global DNA methylation is associated with several processes such as genomic imprinting, X-chromosome inactivation, and the repression of repeated elements. Importantly, dysregulation of these cellular events is frequently found during early and late stages of tumorigenesis. DNA methylation involves the covalent modification of DNA mediated by DNMT, which transfer methyl groups (-CH3) from S-adenosyl-L-methionine (SAM) to cytosine in the so-called CpG islands. The CpG regions are contained in large DNA sequences found mainly in gene promoters, intergenic regions and repeated elements. Aberrant DNA methylation patterns play a crucial role in genomic instability, activation of oncogenes and silencing of tumor suppressor genes involved in cell proliferation, cell cycle, DNA repair, stress response and apoptosis. These alterations are common during the development and progression of carcinogenesis. Several studies have showed the impact of hypomethylation or hypermethylation of DNA sequences associated with the transcriptional regulation of cancer-related genes. For instance, LINE-1 gene hypomethylation is associated with different clinical-pathological characteristics in lung cancer; early carcinogenesis in breast cancer, and metastasis in colorectal adenocarcinoma. On the other hand, hypomethylation of specific genes like TTF-3, MUC4, and CT45 frequently occur in prostate, pancreatic and ovarian cancers. The hypermethylation of RASSF1A gene has been identified as a diagnostic marker in lung cancer, whereas it contributes to increased mortality in women with breast cancer. Hypermethylation of RASSF1A also has been related with high risk of ovarian cancer. Other studies showed that hypermethylation of PDE3A gene modulated the response to therapy in cisplatin-resistant non-small cell lung cancer (NSCLC). In addition, hypermethylation of genes such as NDN activated the WNT signaling pathway contributing to cell proliferation of colorectal cancer cells. These examples illustrate the impact of alterations in epigenetic mechanisms in the development of diverse types of human cancers.

Histone Modifications

3Histones are alkaline proteins located in the nucleus of eukaryotic cells. Their function is to package DNA into structural units called nucleosomes. The core component of nucleosome is the histone octamer, which is formed by two copies of each histone H2A, H2B, H3; whereas histone H1 binds to the linker DNA between nucleosomes. The histones have flexible tails that protrude from the lateral surface of the nucleosome. These tails are susceptible to suffer different chemical modifications in the lysine (K), serine (S), threonine (T) and arginine (R) amino acids. Histone modifications in specific amino acids residues (termed histone code) modulate the chromatin structure and gene expression. Histone proteins have structural and functional roles in the transition between the active and inactive chromatin states. When chromatin is highly packed (heterochromatin) the transcription of genes is blocked; whereas when the chromatin is less condensed (euchromatin) the transcription is activated. Histones can be modified covalently in the N- and C-terminal tails by two families of enzymes; the histone acetyltransferases (HATs) that transfer acetyl groups from coenzyme A (CoA), and the histone deacetylases (HDACs) that remove the acetyl groups from specific amino acid residues. Histone modifications regulate different biological processes such as transcription, chromosome packaging, and DNA damage response and repair. The primary modifications of histones are acetylation, methylation, phosphorylation, ubiquitination, sumoylation, glycosylation and poly ADP ribosylation. The acetylation and methylation are well studied mechanisms of histone modifications, and they are key regulators of cellular proliferation, differentiation, division and plasticity.

4In cancer cells, histones modifications at specific amino acids residues are related to transcription activation or repression. In most species, histone H3 is primarily acetylated at lysines 9, 14, 18, 23, and 56, methylated at arginine 2 and lysines 4, 9, 27, 36, and 79, and phosphorylated at ser10, ser28, Thr3, and Thr11. For instance, gene activation has been associated with trimethylation of lysine 4 on the histone H3 (H3K4me3), acetylation of lysine 9 on the histone H3 (H3K9ac) and monomethylation of lysine 20 on the histone H3 (H3K20me). In contrast, the H3K9me3 and H3K27 epigenetic marks induce repression of gene expression. In prostate cancer, H3K9me2 and H3Ac marks distinguish between tumors from non-malignant tissues, and the H3K4me1 modification was established as a biomarker of tumor progression and a predictor of recurrence after radical prostatectomy. H3K4me and H3K9 modifications were regulated by histone demethylase JMJD2B and promoted hormonal responsiveness in breast cancer patients. In early-stage of colon cancer (TNM stage I and II) low nuclear expression of H3K4me3 and high expression of H3K9me3 and H4K20me3 were associated with good prognosis.

Polyphenols Classification and Functions

5Polyphenols are the most important group of phytochemicals present in plants. They are secondary plant metabolites found in the fruits, vegetables, cereals, and natural beverages. These compounds exhibit biological roles in human cells acting as antioxidants, antimicrobials, detoxification, immune system stimulation, decrease of platelets aggregation, modulation of hormonal metabolism and anti-tumoral agents. Research in recent years strongly supports a role for polyphenols as important molecules protecting cells from DNA damage. Therefore, polyphenols have important benefits in the prevention and treatment of oncologic diseases. Currently, the main polyphenols studied in cancer cells are the phenolic acids, flavonoids, stilbenes, and lignans (Figure 1).

Phenolic Acids

6The hydroxycinnamic acids are the more frequent simple phenolic compounds found in natural sources. The cinnamic acid, p-coumaric acid, ferulic acid, caffeic acid, chlorgenic acid, and rosmarinic acid belong to this class. These acids are rarely found as free form but these compounds can found as glycosylated derivatives or esters of quinic acid, shikimic acid, and tartaric acid in processed food that has undergone freezing, sterilization, or fermentation. High concentrations of hydroxybenzoic acid are contained in red fruits, black radish, and onions. Hydroxybenzoic acids form complex structures such as hydrolysable tannins. These tannins also have multiple health benefits including cancer suppression. Combination of caffeic and quinic acid form the chlorogenic acid, which is found in many types of fruit as blueberries, kiwis, plums, cherries, and at high concentrations in coffee. The curcumin acts as antioxidant and anti-inflammatory and has been reported that it has multiple effects in cancer cells.

Flavonoids

7Flavonoids are natural molecules containing variable phenolic structures composed of 15-carbon (C6–C3–C6) skeleton and two benzene rings joined by a linear 3-carbon chain. Subgroups of flavonoids are: flavonols such as quercetin, kaempferol, and myricetin. They are found in onions, curly, broccoli, and blueberries. The flavanones as eriodictyol, hesperetin, and naringenin are found in grapefruit, oranges, and lemons. The isoflavonoids including daidzein, genistein, and glycitein are presents in leguminous. The flavones as apigenin and luteolin are in cereals. The flavanols as catechin are found in green tea and chocolate, and the anthocyanins including cyanidin, delphinidin, malvidin, pelargonidin, peonidin, and petunidin are present in berries, pears, apples, grapes and peaches. The biological effects of flavonoids have been linked to their anti-obesity, anti-diabetic and anti-oxidative activities. In cancer, these compounds inhibit cell proliferation, induce cytotoxicity, suppression of angiogenesis; and cause cell death by apoptosis (Figure 2).

Stilbenes

8Natural stilbenes are non-flavonoid phytochemicals with polyphenolic structure that containing a 1,2-diphenylethylene nucleus. Stilbenes are found in berries, grapes and peanuts. These compounds have a high potential for the prevention and treatment of different diseases. In cancer cells, they showed antioxidant and anti-inflammatory effects, as well as cell death induction. The main stilbene studied to date in cancer is resveratrol.

Sulforaphane

9Sulforaphane [1-isothiocyanato-4-(methyl-sulfinyl)] butane is the most widely characterized molecule belong to the isothiocyanate group of organosulfur compounds. Sulforaphane (SFN) is produced by the hydrolysis of glucoraphanin after intake of cruciferous vegetables such as broccoli, cabbages, kale, Brussels sprouts, radish, and mustard. This compound displays anti-inflammatory, antibiotic, and antioxidant activities (Figure 2). In cancer cells, SFN acts as potent chemopreventive and anti-tumoral natural agent.

Epigenetic Modulation by Polyphenols in Cancer Pathways

10Recent reports indicate that dietary supplements and natural compounds may restore the normal epigenetic marks which are altered during carcinogenesis. The phytochemicals most studied in cancer are epigallocatechin-gallate (EGCG), quercetin, resveratrol, curcumin, and SFN. Several studies have showed that these natural compounds inhibit several cellular processes associated to cancer (Figure 3). In particular, these compounds blocked the development and progression of tumors by targeting key signaling transducers resulting in the restoration of tumor suppressor genes, and inhibition of oncogenes expression. These effects are mediated, in part, by the modulation of epigenetic machinery which included the regulation of DNMTs and HDACs activities (Figure 3 and Table 1).

Epigenetic Modulation by EGCG in Cancer Cells

11Epigallocatechin-gallate is a polyphenolic catechin mainly found in green tea and its regular intake might significantly reduce the risk of breast and prostate cancer. This natural compound may induce apoptosis and inhibition of cell proliferation by epigenetic mechanisms. It has been reported that EGCG epigenetically reactivated p21/waf1, Bax and PUMA in prostate cancer cells, leading to cell cycle arrest and apoptosis mediated by proteasomal degradation of class I HDACs. Studies of molecular modeling indicated that EGCG directly binds to the enzymatic substrates of DNMT3b and HDAC1 leading to their inhibition and reactivation of tumor suppressor genes such as retinoic acid receptor β, cadherin1 and death-associated protein kinase-1.

12reported that EGCG repressed the hormone responsiveness of androgen receptor (AR) by reducing the acetylation of AR, leading to decreased cell proliferation and promoting cell death in LNCaP prostate cancer cell line. Remarkably, EGCG is a potential epigenetic modifier of DNMTs and HDACs and restores epigenetically silenced genes in skin and cervical cancers. For instance, in skin cancer cells, EGCG significantly decreased the proteins levels of DNMT1, DNMT3a, and DNMT3b and modulated the HDAC activities allowing the transcriptional activation of tumor suppressor genes such as p16 INK4a and Cip1/p21. In esophageal cancer, EGCG induced apoptosis and inhibited cell growth of ECa109 cells through p16 gene demethylation. Moreover, EGCG reactivated the expression of WIF-1 (Wnt inhibitory factor-1) through promoter demethylation and inhibited cell growth by downregulating the Wnt canonical pathway in H460 and A549 lung cancer cell lines. The DNA hypomethylation as a consequence of 5-Aza-dc treatment has been shown to trigger the expression of prometastatic genes in prostate cancer. showed that promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells.

13During chemotherapy, EGCG sensitized the ERα-negative cells to respond to 17β-estradiol and the antagonist tamoxifen. EGCG in combination with the HDAC inhibitor trichostatin A (TSA) reactivated the ERα expression in triple negative MDA-MB-231 breast cancer cells by altering acetylation and methylation of histones and remodeling the chromatin structure. In addition, EGCG in combination with SFN sensitized the ERα-negative breast cancer cells to tamoxifen treatment, thus inhibiting cell proliferation. These examples illustrate how combination of polyphenols with current cancer treatments has a great impact in the inhibition of cancer hallmarks through epigenetic mechanisms suggesting clinical implications in patients therapies.

Epigenetic Modulation by Curcumin in Cancer

14Curcumin is a phenolic component isolated from the roots of plant Curcuma longa (turmeric) widely used in China and India for medicinal purposes. Several studies indicate that curcumin has antioxidant, anti-inflammatory, anti-proliferative, anti-angiogenic, and anti-cancer properties. Moreover, this natural compound has been considered as an excellent non-toxic hypomethylating agent for breast cancer therapy. For instance, curcumin inhibited DNMT1 expression and restored the function of RASSF1A by promoter hypomethylation in estrogen positive MCF-7 breast cancer cell line. Furthermore, curcumin decreased the cell proliferation and breast tumors growth in vivo. Curcumin and 5-aza-dc reactivated the RARβ gene through promoter hypomethylation in H460 lung cancer cells. Moreover, when A549 lung cancer cells were implanted in nude mice and treated with curcumin, tumor growth was significantly decreased. This effect was mediated by increasing of RARβ and decreasing of DNMT3b expression. On the other hand, curcumin induced histone hypoacetylation and apoptosis associated to PARP activity in brain cancer cells. Also, curcumin impeded differentiation of astrocytes and promoted neural differentiation associated with hypoacetylation of H3 and H4. Other studies showed that curcumin increased protein levels of RANK in human glioblastoma cells through a demethylation mechanism. Curcumin-induced histone hypoacetylation enhanced caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. Additionally, low levels of STAT3 caused RANK promoter demethylation inducing its reactivation.

15In the acute myeloid leukemia (AML), curcumin downregulated the expression of DNMT1 in diverse cell lines in vivo and in ex vivo models. Curcumin blocks the positive regulators of DNMT1, p65 and Sp1 decreasing their activity for binding to the promoter region of DNMT1. Additionally, curcumin restored p15INK4b expression by hypomethylation of its promoter inducing cell cycle arrest at G1 phase and apoptosis in vitro. Importantly, in mice implanted with the MV4-11 cell line of AML, curcumin suppressed tumor growth.

16In prostate cancer, curcumin inhibited tumor development in TRAMP mice model due to reversion of methylation status of Nrf2 promoter. Also, curcumin promoted apoptosis of LNCaP cells inhibiting JNK signaling and repressing H3K4me3 epigenetic mark. Combination of curcumin and JQ-1 efficiently suppresses prostate cancer development. In HT29 colon cancer cells, curcumin inhibited the colony formation and decreased methylation of DLEC1 promoter associated to downregulation of DNMT1, DNMT3a, DNMT3b, and HDAC4/5/6/8 proteins. On the other hand, using a genome-wide approach showed that, in contrast to non-specific global hypomethylation induced by 5-aza-CdR, curcumin induced specific changes in DNA methylation of a subset of genes involved in cell viability and proliferation in colorectal cancer cells.

Epigenetic Modulation by Quercetin in Cancer

17Quercetin is a flavonoid found in fruits and vegetables such as onions, red wine, green tea, and apples. In tumor cells, quercetin blocked cell cycle and induced pro-apoptotic effects without affecting normal cells. Moreover, reported that quercetin inhibited the binding of transactivators CREB2, C-Jun, C/EBPβ and NF-κB and blocked the recruitment of the coactivator p300 to COX-2 promoter. Also, quercetin inhibited p300 HAT activity, thereby attenuating the p300-mediated acetylation of NF-κB. On the other hand, showed that quercetin inhibited tumor growth by activation of p16INK4a induced by promoter demethylation in colorectal cancer cells. In leukemic HL-60 cell line, quercetin promotes cell death by FasL expression mediated by H3 acetylation. Combinations of quercetin and curcumin restored protein levels of AR in androgen-receptor negative prostate cancer cells. These effects were mediated by decreasing of DNMT, resulting in global hypomethylation and induction of apoptosis via mitochondrial depolarization.

18Interestingly, the synergistic effects of quercetin and curcumin combined treatment resulted in sensitization of resistant prostatic cancer cells to anti-androgen treatment. In esophageal cancer, combinations of quercetin and sodium butyrate repress tumor growth and cell proliferation which was associated with downregulation of DNMT1, NF-κBp65, HDAC1, and cyclin D1. These combination inhibited HDAC through HDAC-NF-κB signaling. On the other hand, quercetin exerted modulatory effects on proteins that have pivotal role in cell survival, invasiveness, angiogenesis and cell proliferation through inhibition of HDAC1 and DNMT1 in hamster buccal pouch carcinoma.

Epigenetic Modulation by Resveratrol in Cancer

19Resveratrol is a phytoalexin found in many plants such as blueberries, cranberries, and grapes. This polyphenol provide chemopreventive and therapeutics effects in different types of cancer regulating biological functions such as cell proliferation, cell division, apoptosis, angiogenesis and metastasis. In DU145 (mutant p53) and LNCaP (wild type p53) prostate cancer cell lines, resveratrol downregulated the Metastasis Associated Protein 1 (MTA1) leading to destabilization of MTA1/NuRD, a nucleosome remodeling deacetylation (NuRD) corepressor complex that mediates posttranslational modifications of histones and non-histone proteins resulting in transcriptional repression. Downregulation of MTA1 leads to destabilization of MTA1/NuRD thus allowing acetylation/activation of p53. Additionally, combination of resveratrol and HDAC inhibitor SAHA, up-regulated p53 acetylated non-acetylated forms. showed that resveratrol promotes acetylation and reactivation of PTEN by inhibition of the MTA1/HDAC complex, as well as inhibition of the Akt pathway. Thus, MTA1/HDAC complex is a negative regulator of PTEN, which promotes tumor cell survival and progression of prostate cancer.

20In breast cancer cell lines, combination of resveratrol and pterostilbene inhibited cell proliferation, by inducing G2/M phase cell cycle arrest and apoptosis. The dual treatment blocked SIRT1 and decreased the expression of γ-H2AX, thus delaying the early DNA damage response. Also, these compounds cause down-regulation of DNMT1, DNMT3a and DNMT3b in HCC1806 breast cancer cells. Moreover, resveratrol and pterostilbene negatively regulated hTERT leading to inhibition of breast cancer cells growth due to the inhibition of SIRT. In addition, these combinations induced the reactivation of ER-α expression in ER-α negative breast cancer cells, sensitizing tumor cells to 17β-estradiol treatment which was associated to an increase in H3K9 and H4 marks in the ERα promoter.

21Another study has showed the profound effects of resveratrol on global DNA methylation in breast cancer. Our group reported that resveratrol modulated the methylation status of a specific broad set of genes independently of DNMT1 inhibition in MDA-MB-231 breast cancer cells. We performed an Array-PRIMES method (aPRIMES) and DNA microarrays to screen changes in both methylome and transcriptome at genome-wide level in cancer cells treated with resveratrol at 24 and 48 h. The integrative analysis of methylome and transcriptome profiles in response to resveratrol showed that methylation alterations were concordant with changes in mRNA expression. These changes were found in several oncogenes (AURKA, CCNB1, DDIT4, DLGAP5, EYS, FAM83D, IL24, LPXN, NFIL3, PFKFB3, SLC14A1, STC1, GPR110, HK2, MMP9, NFIL3, PSMD11, RUNX2, SH3KBP1) and tumor suppressor genes (AMY2A, IL18, SLIT3, MPHOSPH9, SLC27A2, TMOD2, TTI1, and XYLB). In human A2058 melanoma cells and MDA-MB-468 breast cancer cells, resveratrol reduced the STAT3 acetylation, inducing demethylation of the ER-α promoter region leading to its expression. Resveratrol also sensitized to antiestrogen therapy, decreasing cell viability and cell death. A similar effect was also observed in the M223 melanoma cells resistant to tamoxifen.

Epigenetic Modulation by Sulforaphane in Cancer

22Sulforaphane is a phytochemical derived from cruciferous vegetables. In cancer cells, SFN regulates cell cycle, apoptosis, tumor growth, and tumor progression. reported that the miR-9-3 promoter region is hypermethylated in lung cancer cells. Interestingly, SFN restored the miR-9-3 expression through epigenetic regulation attenuating the DNMT1 activity and DNMT3a, HDAC1, HDAC3, HDAC6, and CDH1 protein expression.

23reported that SFN treatment diminished cell viability and cell proliferation in breast cancer cells. Also, SFN inhibited hTERT in MCF-7 and MDA-MB-231 cancer cells, decreasing DNMT1 and DNMT3a. The downregulation of DNMTs in response to SFN induced CpG demethylation of hTERT thereby facilitating CTCF binding associated with hTERT repression. SFN increased the level of active chromatin markers H3K9ac and acetyl-H4, and suppressed H3K9me3 and H3K27me3 in hTERT promoter. Altogether, these epigenetic events induced breast cancer cells death. Moreover, combined treatments with SFN and withaferin A promoted cell death in breast cancer cells through the inhibition of DNMT1, DNMT3a, and HDAC activities in MCF-7 cells.

24In prostate cancer cells, SFN inhibited the expression of hTERT by changes in histone acetylation and chromatin structure. In LNCaP and DU-145 cells, SFN caused an inhibitory effect in cell proliferation and induced cell cycle arrest at G0/G1 phase. In the LNCaP cell line, SFN modified the global methylation through their negative regulation of DNMT1, DNMT3a, and DNMT3b. Also, SFN induced methylation and inhibited the HDAC activities of hTERT promoter associated with H3K4me2, H3K9me3 and H3K27me3 epigenetic marks. Regarding to DU-145 cells, SFN increased the H3K18Ac and H3K4me2 marks. These modifications were linked with high risk of prostate cancer recurrence. Other effects of SFN in LNCaP cells were the decrease expression of DNMT1 and DNMT3b, and the decrease methylation of cyclin D2 promoter. SFN also caused demethylation of CpGs islands of Nrf2 gene promoter, which acts as regulator in the cellular oxidative stress decreasing the carcinogen-induced tumorigenesis, in TRAMP C1 cells. Moreover, SFN decreased the levels of DNMT1 and DNMT3a and downregulated the expression of HDACs 1, 4, 5, and 7, while increased the levels of the active H3ac chromatin marker. In HeLa cervical cancer cells, SFN exerted negative effects on DNMT1 and HDAC1 activities. showed that SNF increased the expression of RARβ, CDH1, DAPK1, and GSTP1 by restoring the CpG island methylation status and inhibition of epigenetic modulators like DNMT3b and HDAC1 in cervical cancer.

Biological Effects of Fruit and Vegetables Consumption in Human

25Fruit and vegetables and healthy lifestyles are considered protective against cancer development. Recently, The European Prospective Investigation into Cancer and Nutrition (EPIC) realized a multicenter study including 13 European countries for analyzing the association of vegetables and fruit intakes and the cancer risk development for a period from 6.5 to 8.7 years. This center concludes that consumption of vegetables and fruits do not have protector effect in patients with lung, prostate, and breast cancers. However, intake of vegetables and fruits or their combinations, or fruit juice reduced the risk of gastric, esophageal and thyroid cancer. In addition, the intake of red and processed meat were correlated with colorectal cancer and non-cardia stomach cancer risk in subjects carriers of Helicobacter pylori. Furthermore, the consumption of cereal fiber reduced the risk of gastric cancer mainly diffuse type. In contrast, in esophageal adenocarcinoma non-significant trend was found. The effects of intake of vegetables and fruit on prevention of cancer are restricted due to the bioavailability and low concentration of these phytochemical naturals. In recent years, the use complementary and alternative medicine has increased in order to improve the quality and life expectancy of cancer patients. It is important to note that complementary medicine may be used in combination with chemotherapy, radiotherapy or other forms of therapies, but still is not considered as a standard option. However, the establishment of integrative therapies that combines standard care with alternative practices and lifestyles should be considered as a future option in preventive medicine.

Conclusion and Perspectives

26This review provides recent evidences of the dietary polyphenols and their effects anti-tumors by targeting the epigenetic machinery and related mechanisms. These natural phytochemical have potential benefit due to their reverting effects in the epigenetic modifications in tumor suppressor genes and oncogenes, as well as its ability to modulate and restore protein expression levels. The polyphenols cause effects in several biological functions as cell proliferation inhibition, cell cycle arrest, and induction of apoptosis in tumor cells. On the other hand, the epidemiological evidence shows that these compounds may prevents the risk of certain types of cancer development. Thus, it has been considered that these phytochemicals may increase the anti-tumor activity of standard treatments. However, the bioavailability of polyphenolic compounds in the organism is very variable depending on its chemical structure and its origin source, as well as host factors as age, gender, metabolic rate, ethnicity, etc. For all these aspects is required to establish dietary supplements in order to maintain high concentrations in plasma, for that these compounds exert its chemopreventive and therapeutic effects in cancer. Different researches show that polyphenols sensitize tumor cells through different epigenetic targets including oncogenes and tumor suppressor genes as well as DNMTs and HDACs. In addition, the combination of the polyphenols with chemotherapeutic agents exerts a synergistic effect, enhancing the effects of chemotherapeutic agents. However, it is necessary to establish more comprehensive studies that help to understand the complexity of the epigenetic pathways and their mechanisms involved in cancer, especially in highly aggressive and invasive cancers showing resistance to conventional therapies. Future research should be focused in clinical studies in humans for establishing potential personalized regimens for cancer prevention or chemotherapeutic approaches in cancer.

Author Contributions

27CL-C, ÁC-R, and JSL-G organized the entire manuscript, wrote the draft, and revised the last version of manuscript. MM-F, ÁC-R, and JSL-G wrote the introduction, epigenetic mechanisms, and phytochemicals sections. DG-R, ER-G, and HA-dlV wrote the epigenetic modulation by EGCG and curcumin in cancer sections. ÁC-R, JSL-G, and ONHdlC wrote the epigenetic modulation by quercetin, resveratrol, and SFN sections. ÁC-R, LAM and MM-F wrote the modulation of signaling pathways by polyphenols sections. Figure 1–3, as well as Table 1 were designed and made by ÁC-R, JSL-G and ONHdlC.

Conflict of Interest Statement

28The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 170

1.
Abbas A. Hall J. A. Patterson W. L. III Ho E. Hsu A. Al-Mulla F. (2016 ). Sulforaphane modulates telomerase activity via epigenetic regulation in prostate cancer cell lines. Biochem. Cell Biol. 94 71–81.
Not in our library10.1139/bcb-2015-0038
2.
Abdallah R. Xiong Y. Lancaster J. M. Judson P. L. (2015 ). Complementary and alternative medicine use in women with gynecologic malignancy presenting for care at a comprehensive cancer center. Int. J. Gynecol. Cancer 25 1724–1730.
Not in our library10.1097/igc.0000000000000549
3.
Adams M. Jewell A. P. (2007 ). The use of complementary and alternative medicine by cancer patients. In International Seminars in Surgical Oncology. BioMed. Central 4:10.
Not in our library10.1186/1477-7800-4-10
4.
Adjakly M. Bosviel R. Rabiau N. Boiteux J. P. Bignon Y. J. Guy L. (2011 ). DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines. Epigenomics 3 795–803.
Not in our library10.2217/epi.11.103
5.
Adjakly M. Ngollo M. Lebert A. Dagdemir A. Penault-Llorca F. Boiteux J. P. (2014 ). Comparative effects of soy phytoestrogens and 17β-estradiol on DNA methylation of a panel of 24 genes in prostate cancer cell lines. Nutr. Cancer 66 474–482.
Not in our library10.1080/01635581.2014.884236
6.
Aggarwal R. Jha M. Shrivastava A. Jha A. K. (2015 ). Natural compounds: role in reversal of epigenetic changes. Biochemistry 80 972–989.
Not in our library10.1134/s0006297915080027
7.
Ali Khan M. K. Sundaram M. Hamza A. Quraishi U. Gunasekera D. Ramesh L. (2015 ). Sulforaphane reverses the expression of various tumor suppressor genes by targeting DNMT3B and HDAC1 in human cervical cancer cells. Evid. Based Complement. Alternat. Med.
Not in our library10.1155/2015/412149
8.
Atwell L. L. Beaver L. M. Shannon J. Williams D. E. Dashwood R. H. Ho E. (2015 ). Epigenetic regulation by sulforaphane: opportunities for breast and prostate cancer chemoprevention. Curr. Pharmacol. Rep. 1 102–111.
Not in our library10.1007/s40495-014-0002-x
9.
Bag A. Bag N. (2018 ). Tea polyphenols and prevention of epigenetic aberrations in cancer. J. Nat. Sci. Biol. Med. 9 2–5.
Not in our library10.4103/jnsbm.jnsbm_46_17
10.
Bannister A. J. Kouzarides T. (2011 ). Regulation of chromatin by histone modifications. Cell Res. 21:381.
Not in our library10.1038/cr.2011.22
11.
Bégin P. Nadeau K. C. (2014 ). Epigenetic regulation of asthma and allergic disease. Allergy Asthma Clin. Immunol. 10:27.
Not in our library10.1186/1710-1492-10-27
12.
Benard A. Goossens-Beumer I. J. van Hoesel A. Q. de Graaf W. Horati H. Putter H. (2014 ). Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early-stage colon cancer. BMC Cancer 14:531.
Not in our library10.1186/1471-2407-14-531
13.
Berdasco M. Esteller M. (2010 ). Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev. Cell 19 698–711.
Not in our library10.1016/j.devcel.2010.10.005
14.
Berletch J. B. Liu C. Love W. K. Andrews L. G. Katiyar S. K. Tollefsbol T. O. (2008 ). Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. J. Cell. Biochem. 103 509–519.
Not in our library10.1002/jcb.21417
15.
The therapeutic potential of resveratrol: a review of clinical trials · 2017
No notice
16.
Bishayee K. Khuda-Bukhsh A. R. Huh S. O. (2015 ). PLGA-loaded gold-nanoparticles precipitated with quercetin downregulate HDAC-Akt activities controlling proliferation and activate p53-ROS crosstalk to induce apoptosis in hepatocarcinoma cells. Mol. Cells 38 518–527.
Not in our library10.14348/molcells.2015.2339
17.
Biterge B. (2016 ). A mini review on post-translational histone modifications. MOJ Cell Sci. Rep. 3 26–28.
Not in our library10.15406/mojcsr.2016.03.00047
18.
Boffetta P. Couto E. Wichmann J. Ferrari P. Trichopoulos D. Bueno-de-Mesquita H. B. (2010 ). Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst. 102 529–537.
Not in our library10.1093/jnci/djq072
19.
Borriello A. (2017 ). Resveratrol in cancer prevention and treatment: focusing on molecular targets and mechanism of action. Multidiscip. Dig. Publish. Inst. Proc. 1:976
Not in our library10.3390/proceedings1100976
20.
Bosviel R. Dumollard E. Déchelotte P. Bignon Y. J. Bernard-Gallon D. (2012 ). Can soy phytoestrogens decrease DNA methylation in BRCA1 and BRCA2 oncosuppressor genes in breast cancer? OMICS 16 235–244.
Not in our library10.1089/omi.2011.0105
21.
Chahar M. K. Sharma N. Dobhal M. P. Joshi Y. C. (2011 ). Flavonoids: a versatile source of anticancer drugs. Pharmacogn. Rev. 5 1–12.
Not in our library10.4103/0973-7847.79093
22.
Chen H. Landen C. N. Li Y. Alvarez R. D. Tollefsbol T. O. (2013 ). Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Exp. Cell Res. 319 697–706.
Not in our library10.1016/j.yexcr.2012.12.026
23.
Chen Y. C. Kliethermes B. Sauter E. R. (2012 ). Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr. Cancer 64 393–390.
Not in our library10.1080/01635581.2012.654926
24.
Chirumbolo S. (2013 ). Quercetin in cancer prevention and therapy. Integr. Cancer Ther. 12 97–102.
Not in our library10.1177/1534735412448215
25.
Choudhury M. Pandey R. S. Clemens D. L. Davis J. W. Lim R. W. Shukla S. D. (2009 ). Silencing of histone acetyltransferase GCN5 affects gene expression in human hepatoma cells: a gene array analysis. FASEB J. 23(1 Suppl.), 585–588.
Not in our library10.1016/j.alcohol.2010.12.003
26.
Clarke J. D. Hsu A. Yu Z. Dashwood R. H. Ho E. (2011 ). Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells. Mol. Nutr. Food Res. 55 999–1009.
Not in our library10.1002/mnfr.201000547
27.
Cohen I. Poręeba E. Kamieniarz K. Schneider R. (2011 ). Histone modifiers in cancer: friends or foes? Genes Cancer 2 631–647.
Not in our library10.1177/1947601911417176
28.
Cui Y. Lu C. Liu L. Sun D. Yao N. Tan S. (2008 ). Reactivation of methylation-silenced tumor suppressor gene p16INK4a by nordihydroguaiaretic acid and its implication in G1 cell cycle arrest. Life Sci. 82 247–255.
Not in our library10.1016/j.lfs.2007.11.013
29.
Cutter A. R. Hayes J. J. (2015 ). A brief review of nucleosome structure. FEBS Lett. 589(20 Part A), 2914–2922.
Not in our library10.1016/j.febslet.2015.05.016
30.
Deb G. Gupta S. (2015 ). “Natural phytochemicals as epigenetic modulators,” in Genomics, Proteomics and Metabolomics in Nutraceuticals and Functional Foods, eds Bagchi D. Swaroop A. Bagchi M. (Hoboken, NJ: Wiley), 424–439.
Not in our library10.1002/9781118930458.ch34
31.
Dhar S. Kumar A. Li K. Tzivion G. Levenson A. S. (2015 ). Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer. Biochim. Biophys. Acta Mol. Cell Res. 1853 265–275.
Not in our library10.1016/j.bbamcr.2014.11.004
32.
Du L. Xie Z. Wu L. C. Chiu M. Lin J. Chan K. K. (2012 ). Reactivation of RASSF1A in breast cancer cells by curcumin. Nutr. cancer 64 1228–1235.
Not in our library10.1080/01635581.2012.717682
33.
Ehrlich M. (2009 ). DNA hypomethylation in cancer cells. Epigenomics 1 239–259.
Not in our library10.2217/epi.09.33
34.
El Gharras H. (2009 ). Polyphenols: food sources, properties and applications–a review. Int. J. Food Sci. Technol. 44 2512–2518.
Not in our library10.1111/j.1365-2621.2009.02077.x
35.
Ellinger J. Kahl P. von der Gathen J. Rogenhofer S. Heukamp L. C. Gütgemann I. (2009 ). Global levels of histone modifications predict prostate cancer recurrence. Prostate 70 61–69.
Not in our library10.1002/pros.21038
36.
El-Sherif W. T. Sayed S. K. Galal S. H. Makhlouf H. A. Hassan A. T. Yousef H. A. (2016 ). Diagnostic role of RASSF1A and p16INK4a promoter gene hypermethylation in serum DNA of lung cancer patients: clinicopathological significance. Egypt. J. Immunol. 23 1–16.
Not in our library
37.
LINE-1 Hypomethylation in Cancer Is Highly Variable and Inversely Correlated with Microsatellite Instability · 2007
No notice
38.
Esteller M. (2005 ). Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol. 45 629–656.
Not in our library10.1146/annurev.pharmtox.45.120403.095832
39.
Esteller M. (2008 ). Epigenetics in cancer. New Engl. J. Med. 358 1148–1159.
Not in our library10.1056/nejmra072067
40.
Esteller M. (2011 ). Epigenetic changes in cancer. F1000 Biol. Rep. 3:9.
Not in our library10.3410/b3-9
41.
Esteller M. Herman J. G. (2002 ). Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J. Pathol. 196 1–7.
Not in our library10.1002/path.1024
42.
Flavonoids: biosynthesis, biological functions, and biotechnological applications · 2012
No notice
43.
Fang M. Z. Chen D. Sun Y. Jin Z. Christman J. K. Yang C. S. (2005 ). Reversal of hypermethylation and reactivation of p16INK4a, RARβ, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 11 7033–7041.
Not in our library10.1158/1078-0432.ccr-05-0406
44.
Fang M. Z. Wang Y. Ai N. Hou Z. Sun Y. Lu H. (2003 ). Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 63 7563–7570.
Not in our library
45.
Feng C. Ho Y. Sun C. Xia G. Ding Q. Gu B. (2017 ). Epigallocatechin gallate inhibits the growth and promotes the apoptosis of bladder cancer cells. Exp. Ther. Med. 14 3513–3518.
Not in our library10.3892/etm.2017.4981
46.
A Critical Review on Polyphenols and Health Benefits of Black Soybeans · 2017
No notice
47.
Gao L. Cheng D. Yang J. Wu R. Li W. Kong A. N. (2018 ). Sulforaphane epigenetically demethylates the CpG sites of the miR-9-3 promoter and reactivates miR-9-3 expression in human lung cancer A549 cells. J. Nutr. Biochem. 56 109–115.
Not in our library10.1016/j.jnutbio.2018.01.015
48.
Gao Z. H. I. Xu Z. Hung M. S. Lin Y. C. Wang T. Gong M. (2009 ). Promoter demethylation of WIF-1 by epigallocatechin-3-gallate in lung cancer cells. Anticancer Res. 29 2025–2030.
Not in our library
49.
Quercetin and Cancer Chemoprevention · 2011
No notice
50.
Glant T. T. Mikecz K. Rauch T. A. (2014 ). Epigenetics in the pathogenesis of rheumatoid arthritis. BMC Med. 12:35.
Not in our library10.1186/1741-7015-12-35
51.
Gonzālez C. A. Jakszyn P. Pera G. Agudo A. Bingham S. Palli D. (2006 ). Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst. 98 345–354.
Not in our library10.1093/jnci/djj071
52.
Gonzalez C. A. Lujan-Barroso L. Bueno-de-Mesquita H. B. Jenab M. Duell E. J. Agudo A. (2012 ). Fruit and vegetable intake and the risk of gastric adenocarcinoma: a reanalysis of the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study after a longer follow-up. Int. J. Cancer 131 2910–2919.
Not in our library10.1002/ijc.27565
53.
Gonzalez C. A. Riboli E. (2006 ). Diet and cancer prevention: where we are, where we are going. Nutr. Cancer 56 225–231.
Not in our library10.1207/s15327914nc5602_14
54.
Greenlee H. (2012 ). Natural Products for Cancer Prevention. In Seminars in Oncology Nursing, Vol. 28. Philadelphia, PA: WB Saunders, 29–44
Not in our library10.1016/j.soncn.2011.11.004
55.
Guo Y. Shu L. Zhang C. Su Z. Y. Kong A. N. T. (2015 ). Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1. Biochem. Pharmacol. 94 69–78.
Not in our library10.1016/j.bcp.2015.01.009
56.
Guo Y. Su Z. Y. Kong A. N. T. (2015 ). Current perspectives on epigenetic modifications by dietary chemopreventive and herbal phytochemicals. Curr. Pharmacol. Rep. 1 245–257.
Not in our library10.1007/s40495-015-0023-0
57.
Green tea polyphenols induce p53-dependent and p53-independent apoptosis in prostate cancer cells through two distinct mechanisms. · 2012
Not checked
58.
Haldrup C. Vestergaard E. M. Wild P. J. Høyer S. Sørensen K. D. (2017 ). Comprehensive evaluation of TFF3 promoter hypomethylation and molecular biomarker potential for prostate cancer diagnosis and prognosis. Int. J. Mol. Sci. 18:E2017.
Not in our library10.3390/ijms18092017
59.
Hardman W. E. (2014 ). Diet components can suppress inflammation and reduce cancer risk. Nutr. Res. Pract. 8 233–240.
Not in our library10.4162/nrp.2014.8.3.233
60.
Henning S. M. Wang P. Said J. Magyar C. Castor B. Doan N. (2012 ). Polyphenols in brewed green tea inhibit prostate tumor xenograft growth by localizing to the tumor and decreasing oxidative stress and angiogenesis. J. Nutr. Biochem. 23 1537–1542.
Not in our library10.1016/j.jnutbio.2011.10.007
61.
Curcumin: A Review of Its Effects on Human Health · 2017
No notice
62.
Hsieh C. J. Kuo P. L. Hsu Y. C. Huang Y. F. Tsai E. M. Hsu Y. L. (2014 ). Arctigenin, a dietary phytoestrogen, induces apoptosis of estrogen receptor-negative breast cancer cells through the ROS/p38 MAPK pathway and epigenetic regulation. Free Radic. Biol. Med. 67 159–170.
Not in our library10.1016/j.freeradbiomed.2013.10.004
63.
Hsu A. Wong C. P. Yu Z. Williams D. E. Dashwood R. H. Ho E. (2011 ). Promoter de-methylation of cyclin D2 by sulforaphane in prostate cancer cells. Clin. Epigenetics 3:3.
Not in our library10.1186/1868-7083-3-3
64.
Hu Y. H. Chen Q. Lu Y. X. Zhang J. M. Lin C. Zhang F. (2017 ). Hypermethylation of NDN promotes cell proliferation by activating the Wnt signalin pathway in colorectal cancer. Oncotarget 8:46191.
Not in our library10.18632/oncotarget.17580
65.
Hur K. Cejas P. Feliu J. Moreno-Rubio J. Burgos E. Boland C. R. (2014 ). Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut 63 635–646.
Not in our library10.1136/gutjnl-2012-304219
66.
Imperatori A. Sahnane N. Rotolo N. Franzi F. Nardecchia E. Libera L. (2017 ). LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer. Lung Cancer 108 83–89.
Not in our library10.1016/j.lungcan.2017.03.003
67.
Jabeena S. Hanifa M. A. Khanb M. M. Qadric R. W. K. (2014 ). Natural products sources and their active compounds on disease prevention: a. health. Int. J. Chem. Biochem. Sci. 6:7.
Not in our library
68.
Jiang A. Wang X. Shan X. Li Y. Wang P. Jiang P. (2015 ). Curcumin reactivates silenced tumor suppressor gene RARβ by reducing DNA methylation. Phytother. Res. 29 1237–1245.
Not in our library10.1002/ptr.5373
69.
Jin B. Li Y. Robertson K. D. (2011 ). DNA methylation: superior or subordinate in the epigenetic hierarchy? Genes Cancer 2 607–617.
Not in our library10.1177/1947601910393957
70.
Joozdani F. A. Yari F. Joozdani P. A. Nafisi S. (2015 ). Interaction of Sulforaphane with DNA and RNA. PLoS One 10:e0127541.
Not in our library10.1371/journal.pone.0127541
71.
Kagohara L. T. Stein-O’Brien G. L. Kelley D. Flam E. Wick H. C. Danilova L. V. (2017 ). Epigenetic regulation of gene expression in cancer: techniques, resources and analysis. Brief. Funct. Genom. 17 49–63.
Not in our library10.1093/bfgp/elx018
72.
Kai L. Samuel S. K. Levenson A. S. (2010 ). Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int. J. Cancer 126 1538–1548.
Not in our library10.1002/ijc.24928
73.
Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer · 2015
No notice
74.
Kala R. Tollefsbol T. O. (2016 ). A novel combinatorial epigenetic therapy using resveratrol and pterostilbene for restoring estrogen receptor-α (ERα) expression in ERα-negative breast cancer cells. PLoS One 11:e0155057.
Not in our library10.1371/journal.pone.0155057
75.
Kang S. K. Cha S. H. Jeon H. G. (2006 ). Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. Stem Cells Dev. 15 165–174.
Not in our library10.1089/scd.2006.15.165
76.
Kanwal R. Sharma H. Gupta S. (2011 ). Plant flavonoid apigenin preferentially binds with GC-rich DNA sequences and inhibits DNA methylation. Cancer Res. 71(8 Suppl.), 3683–3683.
Not in our library10.1158/1538-7445.am2011-3683
77.
Karlić R. Chung H. R. Lasserre J. Vlahoviček K. Vingron M. (2010 ). Histone modification levels are predictive for gene expression. Proc. Natl. Acad. Sci. U.S.A. 107 2926–2931.
Not in our library10.1073/pnas.0909344107
78.
Molecular Mechanisms of the Anti-Obesity and Anti-Diabetic Properties of Flavonoids · 2016
No notice
79.
Khan M. A. Hussain A. Sundaram M. K. Alalami U. Gunasekera D. Ramesh L. (2015 ). (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells. Oncol. Rep. 33 1976–1984.
Not in our library10.3892/or.2015.3802
80.
Khor T. O. Huang Y. Wu T. Y. Shu L. Lee J. Kong A. N. T. (2011 ). Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem. Pharmacol. 82 1073–1078.
Not in our library10.1016/j.bcp.2011.07.065
81.
Kim J. K. Park S. U. (2016 ). Current potential health benefits of sulforaphane. EXCLI J. 15:571.
Not in our library10.17179/excli2016-485
82.
Kim Y. H. Lee D. H. Jeong J. H. Guo Z. S. Lee Y. J. (2008 ). Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem. Pharmacol. 75 1946–1958.
Not in our library10.1016/j.bcp.2008.02.016
83.
Kocaadam B. Şanlier N. (2017 ). Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit. Rev. Food Sci. Nutr. 57 2889–2895.
Not in our library10.1080/10408398.2015.1077195
84.
Kumar U. Sharma U. Rathi G. (2017 ). Reversal of hypermethylation and reactivation of glutathione S-transferase pi 1 gene by curcumin in breast cancer cell line. Tumor Biol. 39:1010428317692258.
Not in our library10.1177/1010428317692258
85.
Lawrence M. Daujat S. Schneider R. (2016 ). Lateral thinking: how histone modifications regulate gene expression. Trends Genet. 32 42–56.
Not in our library10.1016/j.tig.2015.10.007
86.
Lee H. Zhang P. Herrmann A. Yang C. Xin H. Wang Z. (2012 ). Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc. Natl. Acad. Sci. U.S.A. 109 7765–7769.
Not in our library10.1073/pnas.1205132109
87.
Lee W. J. Chen Y. R. Tseng T. H. (2011 ). Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells. Oncol. Rep. 25 583–591.
Not in our library10.3892/or.2010.1097
88.
Lee Y. H. Kwak J. Choi H. K. Choi K. C. Kim S. Lee J. (2012 ). EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity. Int. J. Mol. Med. 30 69–74.
Not in our library10.3892/ijmm.2012.966
89.
Leszinski G. Gezer U. Siegele B. Stoetzer O. Holdenrieder S. (2012 ). Relevance of histone marks H3K9me3 and H4K20me3 in cancer. Anticancer Res. 32 2199–2205.
Not in our library
90.
Li S. (2012 ). Implication of posttranslational histone modifications in nucleotide excision repair. Int. J. Mol. Sci. 13 12461–12486.
Not in our library10.3390/ijms131012461
91.
Li W. Su Z. Y. Guo Y. Zhang C. Wu R. Gao L. (2018 ). Curcumin derivative epigenetically reactivates Nrf2 antioxidative stress signaling in mouse prostate cancer TRAMP C1 cells. Chem. Res. Toxicol. 31 88–96.
Not in our library10.1021/acs.chemrestox.7b00248
92.
Li Y. Chen H. Hardy T. M. Tollefsbol T. O. (2013 ). Epigenetic regulation of multiple tumor-related genes leads to suppression of breast tumorigenesis by dietary genistein. PLoS One 8:e54369.
Not in our library10.1371/journal.pone.0054369
93.
Li Y. Go V. L. W. Sarkar F. H. (2015 ). The role of nutraceuticals in pancreatic cancer prevention and therapy: targeting cellular signaling, miRNAs and epigenome. Pancreas 44 1–10.
Not in our library10.1097/mpa.0000000000000257
94.
Li Y. Lu D. G. Ma Y. M. Liu H. (2017a ). Association between Retinoic acid receptor-β hypermethylation and NSCLC risk: a meta-analysis and literature review. Oncotarget 8:5814.
Not in our library10.18632/oncotarget.14023
95.
Li Y. Meeran S. M. Tollefsbol T. O. (2017b ). Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression. Sci. Rep. 7:9345.
Not in our library10.1038/s41598-017-09764-3
96.
Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells · 2010
No notice
97.
Lim D. H. Maher E. R. (2010 ). DNA methylation: a form of epigenetic control of gene expression. Obstetr. Gynaecol. 12 37–42.
Not in our library10.1576/toag.12.1.037.27556
98.
Curcumin Modulates DNA Methylation in Colorectal Cancer Cells · 2013
No notice
99.
Linseisen J. Kim C. A. Overvad K. Nielsen M. R. S. Tjønneland A. Olsen A. (2010 ). Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst. 102 529–537.
Not in our library10.1093/jnci/djq072
100.
Liu X. Sun C. Liu B. Jin X. Li P. Zheng X. (2016 ). Genistein mediates the selective radiosensitizing effect in NSCLC A549 cells via inhibiting methylation of the keap1 gene promoter region. Oncotarget 7:27267.
Not in our library10.18632/oncotarget.8403
101.
Liu Y. Zhou J. Hu Y. Wang J. Yuan C. (2017 ). Curcumin inhibits growth of human breast cancer cells through demethylation of DLC1 promoter. Mol. Cell. Biochem. 425 47–58.
Not in our library10.1007/s11010-016-2861-4
102.
Luczak M. W. Jagodziński P. P. (2006 ). The role of DNA methylation in cancer development. Folia Histochem. Cytobiol. 44 143–154.
Not in our library
103.
Mahmoud A. M. Al-Alem U. Ali M. M. Bosland M. C. (2015 ). Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation. J. Steroid Biochem. Mol. Biol. 152 62–75.
Not in our library10.1016/j.jsbmb.2015.04.018
104.
Majid S. Dar A. A. Shahryari V. Hirata H. Ahmad A. Saini S. (2010 ). Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer 116 66–76.
Not in our library10.1002/cncr.24662
105.
Majid S. Kikuno N. Nelles J. Noonan E. Tanaka Y. Kawamoto K. (2008 ). Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res. 68 2736–2744.
Not in our library10.1158/0008-5472.can-07-2290
106.
Manach C. Scalbert A. Morand C. Rémésy C. Jiménez L. (2004 ). Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 79 727–747.
Not in our library10.1093/ajcn/79.5.727
107.
Mariño-Ramírez L. Kann M. G. Shoemaker B. A. Landsman D. (2005 ). Histone structure and nucleosome stability. Expert Rev. Proteomics 2 719–729.
Not in our library10.1586/14789450.2.5.719
108.
Marmorstein R. Zhou M. M. (2014 ). Writers and readers of histone acetylation: structure, mechanism, and inhibition. Cold Spring Harb. Perspect. Biol. 6:a018762.
Not in our library10.1101/cshperspect.a018762
109.
McCleary-Wheeler A. L. Lomberk G. A. Weiss F. U. Schneider G. Fabbri M. Poshusta T. L. (2013 ). Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett. 328 212–221.
Not in our library10.1016/j.canlet.2012.10.005
110.
Medina-Aguilar R. Pérez-Plasencia C. Marchat L. A. Gariglio P. Mena J. G. Cuevas S. R. (2016 ). Methylation landscape of human breast cancer cells in response to dietary compound resveratrol. PLoS One 11:e0157866.
Not in our library10.1371/journal.pone.0157866
111.
Meeran S. M. Patel S. N. Chan T. H. Tollefsbol T. O. (2011 ). A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells. Cancer Prevent. Res. 4 1243–1254.
Not in our library10.1158/1940-6207.capr-11-0009
112.
Sulforaphane Causes Epigenetic Repression of hTERT Expression in Human Breast Cancer Cell Lines · 2010
No notice
113.
Mendez G. Agudo A. Bueno-de-Mesquita H. B. Palli D. Boeing H. (2008 ). Cereal fiber intake may reduce risk of gastric adenocarcinomas: the EPIC-EURGAST study (International Journal of Cancer (2007) 121, (1618-1623)). Int. J. Cancer 123:2228.
Not in our library10.1002/ijc.22896
114.
Meng J. Tong Q. Liu X. Yu Z. Zhang J. Gao B. (2017 ). Epigallocatechin-3-gallate inhibits growth and induces apoptosis in esophageal cancer cells through the demethylation and reactivation of the p16 gene. Oncol. Lett. 14 1152–1156.
Not in our library10.3892/ol.2017.6248
115.
Molassiotis A. Fernadez-Ortega P. Pud D. Ozden G. Scott J. A. Panteli V. (2005 ). Use of complementary and alternative medicine in cancer patients: a European survey. Ann. Oncol. 16 655–663.
Not in our library10.1093/annonc/mdi110
116.
Moore L. D. Le T. Fan G. (2013 ). DNA methylation and its basic function. Neuropsychopharmacology 38:23
Not in our library10.1038/nnp.2012.112
117.
Mossman D. Scott R. J. (2006 ). Epimutations, inheritance and causes of aberrant DNA methylation in cancer. Hered. Cancer Clin. Pract. 4 75–80.
Not in our library10.1186/1897-4287-4-2-75
118.
Nandakumar V. Vaid M. Katiyar S. K. (2011 ). (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p 16 INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis 32 537–544.
Not in our library10.1093/carcin/bgq285
119.
Natarajan T. Anandhi M. Aiswarya D. Ramkumar R. Kumar S. Perumal P. (2016 ). Idaein chloride induced p53 dependent apoptosis in cervical cancer cells through inhibition of viral oncoproteins. Biochimie 121 13–20.
Not in our library10.1016/j.biochi.2015.11.008
120.
Niesen D. B. Hessler C. Seeram N. P. (2013 ). Beyond resveratrol: a review of natural stilbenoids identified from 2009–2013. J. Berry Res. 3 181–196.
Not in our library10.3233/jbr-130062
121.
Nørgaard M. Haldrup C. Storebjerg T. M. Vestergaard E. M. Wild P. J. Høyer S. (2017 ). Comprehensive Evaluation of TFF3 promoter hypomethylation and molecular biomarker potential for prostate cancer diagnosis and prognosis. Int. J. Mol. Sci. 18:E2017.
Not in our library10.3390/ijms18092017
122.
Pandey M. Kaur P. Shukla S. Abbas A. Fu P. Gupta S. (2012 ). Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study. Mol. Carcinog. 51 952–962.
Not in our library10.1002/mc.20866
123.
Pandey M. Shukla S. Gupta S. (2010 ). Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int. J. Cancer 126 2520–2533.
Not in our library10.1002/ijc.24988
124.
Papoutsis A. J. Lamore S. D. Wondrak G. T. Selmin O. I. Romagnolo D. F. (2010 ). Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells. J. Nutr. 140 1607–1614.
Not in our library10.3945/jn.110.123422
125.
Park S. Y. Seo A. N. Jung H. Y. Gwak J. M. Jung N. Cho N. Y. (2014 ). Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer. PLoS One 9:e100429.
Not in our library10.1371/journal.pone.0100429
126.
Prakash K. Fournier D. (2017 ). Histone code and higher-order chromatin folding: a hypothesis. Genom. Comput. Biol. 3:41
Not in our library10.18547/gcb.2017.vol3.iss2.e41
127.
Priyadarsini R. V. Vinothini G. Murugan R. S. Manikandan P. Nagini S. (2011 ). The flavonoid quercetin modulates the hallmark capabilities of hamster buccal pouch tumors. Nutr. Cancer 63 218–226.
Not in our library10.1080/01635581.2011.523503
128.
Rajendran P. Delage B. Dashwood W. M. Yu T. W. Wuth B. Williams D. E. (2011 ). Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly. Mol. Cancer 10:68.
Not in our library10.1186/1476-4598-10-68
129.
Rezk N. A. Mohamed R. H. Alnemr A. A. Harira M. (2018 ). Promoter methylation of RASSF1A gene in egyptian patients with ovarian cancer. Appl. Biochem. Biotechnol. 185 153–162.
Not in our library10.1007/s12010-017-2648-4
130.
Royston K. J. Udayakumar N. Lewis K. Tollefsbol T. O. (2017 ). A novel combination of withaferin a and sulforaphane inhibits epigenetic machinery, cellular viability and induces apoptosis of breast cancer cells. Int. J. Mol. Sci. 18:1092.
Not in our library10.3390/ijms18051092
131.
Saxena M. Saxena J. Nema R. Singh D. Gupta A. (2013 ). Phytochemistry of medicinal plants. J. Pharm. Phytochem. 1 168–182.
Not in our library10.3390/ijms18051092
132.
Shankar E. Kanwal R. Candamo M. Gupta S. (2016 ). “Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges,” in Seminars in Cancer Biology Vol. 40 (Cambridge, MA: Academic Press), 82–99.
Not in our library10.1016/j.semcancer.2016.04.002
133.
Shanmugam M. K. Arfuso F. Arumugam S. Chinnathambi A. Jinsong B. Warrier S. (2018 ). Role of novel histone modifications in cancer. Oncotarget 9:11414.
Not in our library10.18632/oncotarget.23356
134.
Sharma S. Kelly T. K. Jones P. A. (2010 ). Epigenetics in cancer. Carcinogenesis 31 27–36.
Not in our library10.1093/carcin/bgp220
135.
Sharma V. Kumar L. Mohanty S. K. Maikhuri J. P. Rajender S. Gupta G. (2016 ). Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor–synergistic action of quercetin and curcumin. Mol. Cell. Endocrinol. 431 12–23.
Not in our library10.1016/j.mce.2016.04.024
136.
Shi L. Sun L. Li Q. Liang J. Yu W. Yi X. (2011 ). Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 108 7541–7546.
Not in our library10.1073/pnas.1017374108
137.
Shukla S. Meeran S. M. Katiyar S. K. (2014 ). Epigenetic regulation by selected dietary phytochemicals in cancer chemoprevention. Cancer Lett. 355 9–17.
Not in our library10.1016/j.canlet.2014.09.017
138.
Singh C. K. George J. Ahmad N. (2013 ). Resveratrol-based combinatorial strategies for cancer management. Ann. N. Y. Acad. Sci. 1290 113–121.
Not in our library10.1111/nyas.12160
139.
Role of Natural Stilbenes in the Prevention of Cancer · 2015
No notice
140.
Smith B. C. Denu J. M. (2009 ). Chemical mechanisms of histone lysine and arginine modifications. Biochim. Biophys. Acta Gene Regul. Mech. 1789 45–57.
Not in our library10.1016/j.bbagrm.2008.06.005
141.
Sundaram M. K. Ansari M. Z. Mutery A. A. Ashraf M. Nasab R. Rai S. (2017 ). Genistein induces alterations of epigenetic modulatory signatures in human cervical cancer cells. Anticancer Agents Med. Chem. 18 412–421.
Not in our library10.2174/1871520617666170918142114
142.
Tan S. Wang C. Lu C. Zhao B. Cui Y. Shi X. (2009 ). Quercetin is able to demethylate the p16INK4a gene promoter. Chemotherapy 55 6–10.
Not in our library10.1159/000166383
143.
Thakur V. S. Deb G. Babcook M. A. Gupta S. (2014 ). Plant phytochemicals as epigenetic modulators: role in cancer chemoprevention. AAPS J. 16 151–163.
Not in our library10.1208/s12248-013-9548-5
144.
Thakur V. S. Gupta K. Gupta S. (2011 ). Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis 33 377–384.
Not in our library10.1093/carcin/bgr277
145.
Tian F. M. Zhong C. Y. Wang X. N. Meng Y. (2017 ). PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response. Eur. Rev. Med. Pharmacol. Sci. 21 2635–2641.
Not in our library
146.
Tortorella S. M. Royce S. G. Licciardi P. V. Karagiannis T. C. (2015 ). Dietary sulforaphane in cancer chemoprevention: the role of epigenetic regulation and HDAC inhibition. Antioxid. Redox Signal. 22 1382–1424.
Not in our library10.1089/ars.2014.6097
147.
Chemistry and Biochemistry of Dietary Polyphenols · 2010
No notice
148.
Tseng T. H. Chien M. H. Lin W. L. Wen Y. C. Chow J. M. Chen C. K. (2017 ). Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21WAF1/CIP1 expression. Environ. Toxicol. 32 434–444.
Not in our library10.1002/tox.22247
149.
Vardi A. Bosviel R. Rabiau N. Adjakly M. Satih S. Dechelotte P. (2010 ). Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In Vivo 24 393–400.
Not in our library
150.
Verma M. Srivastava S. (2002 ). Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol. 3 755–763.
Not in our library10.1016/s1470-2045(02)00932-4
151.
Wang P. Henning S. M. Heber D. Vadgama J. V. (2015 ). Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J. Nutr. Biochem. 26 408–415.
Not in our library10.1016/j.jnutbio.2014.11.017
152.
Wang Z. Chen H. (2010 ). Genistein increases gene expression by demethylation of WNT5a promoter in colon cancer cell line SW1116. Anticancer Res. 30 4537–4545.
Not in our library
153.
Wong C. P. Hsu A. Buchanan A. Palomera-Sanchez Z. Beaver L. M. Houseman E. A. (2014 ). Effects of sulforaphane and 3, 3′-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. PLoS One 9:e86787.
Not in our library10.1371/journal.pone.0086787
154.
Wu B. Yao X. Nie X. Xu R. (2013 ). Epigenetic reactivation of RANK in glioblastoma cells by curcumin: involvement of STAT3 inhibition. DNA Cell Biol. 32 292–297.
Not in our library10.1089/dna.2013.2042
155.
Quercetin Suppresses Cyclooxygenase-2 Expression and Angiogenesis through Inactivation of P300 Signaling · 2011
No notice
156.
Yadav P. Masroor M. Nandi K. Kaza R. C. M. Jain S. K. Khurana N. (2018 ). Promoter Methylation of BRCA1, DAPK1 and RASSF1A is associated with increased mortality among Indian women with breast cancer. Asian Pac. J. Cancer Prev. 19:443.
Not in our library10.22034/apjcp.2018.19.2.443
157.
Yang W. T. Zheng P. S. (2014 ). Promoter hypermethylation of KLF4 inactivates its tumor suppressor function in cervical carcinogenesis. PLoS One 9:e88827.
Not in our library10.1371/journal.pone.0088827
158.
Curcumin Down-Regulates DNA Methyltransferase 1 and Plays an Anti-Leukemic Role in Acute Myeloid Leukemia · 2013
No notice
159.
Zadi Heydarabad M. Nikasa M. Vatanmakanian M. Azimi A. Farshdousti Hagh M. (2018 ). Regulatory effect of resveratrol and prednisolone on MDR1 gene expression in acute lymphoblastic leukemia cell line (CCRF-CEM): an epigenetic perspective. J. Cell. Biochem. 119 4890–4896.
Not in our library10.1002/jcb.26709
160.
Zaidi S. K. Van Wijnen A. J. Lian J. B. Stein J. L. Stein G. S. (2013 ). Targeting deregulated epigenetic control in cancer. J. Cell. Physiol. 228 2103–2108.
Not in our library10.1002/jcp.24387
161.
Zamora-Ros R. Béraud V. Franceschi S. Cayssials V. Tsilidis K. K. Boutron-Ruault M. C. (2018 ). Consumption of fruits, vegetables and fruit juices and differentiated thyroid carcinoma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Int. J. Cancer 142 449–459.
Not in our library10.1002/ijc.30880
162.
Zhang C. Su Z. Y. Khor T. O. Shu L. Kong A. N. T. (2013 ). Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation. Biochem. Pharmacol. 85 1398–1404.
Not in our library10.1016/j.bcp.2013.02.010
163.
The interplay of histone modifications – writers that read · 2015
No notice
164.
Zhang W. Barger C. J. Link P. A. Mhawech-Fauceglia P. Miller A. Akers S. N. (2015 ). DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Epigenetics 10 736–748.
Not in our library10.1080/15592294.2015.1062206
165.
Zhang Y. Li Q. Chen H. (2013 ). DNA methylation and histone modifications of Wnt genes by genistein during colon cancer development. Carcinogenesis 34 1756–1763.
Not in our library10.1093/carcin/bgt129
166.
Zhao W. Zhou X. Qi G. Guo Y. (2018 ). Curcumin suppressed the prostate cancer by inhibiting JNK pathways via epigenetic regulation. J. Biochem. Mol. Toxicol. 32:e22049.
Not in our library10.1002/jbt.22049
167.
Zheng N. G. Wang J. L. Yang S. L. Wu J. L. (2014 ). Aberrant epigenetic alteration in Eca9706 cells modulated by nanoliposomal quercetin combined with butyrate mediated via epigenetic-NF-κB signaling. Asian Pac. J. Cancer Prev. 15 4539–4543.
Not in our library10.7314/apjcp.2014.15.11.4539
168.
Natural Polyphenols for Prevention and Treatment of Cancer · 2016
No notice
169.
Zhu W. Qin W. Zhang K. Rottinghaus G. E. Chen Y. C. Kliethermes B. (2012 ). Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr. Cancer 64 393–400.
Not in our library10.1080/01635581.2012.654926
170.
Zhu Y. Zhang J. J. Zhu R. Zhu Y. Liang W. B. Gao W. T. (2011 ). The increase in the expression and hypomethylation of MUC4 gene with the progression of pancreatic ductal adenocarcinoma. Med. Oncol. 28 175–184.
Not in our library10.1007/s12032-010-9683-0

Cited by papers we hold 5

Genetics, epigenetics and transgenerational transmission of obesity in children · 2022
Not checked
Role of Flavonoids as Epigenetic Modulators in Cancer Prevention and Therapy · 2021
Not checked
Interaction between Gut Microbiota and Curcumin: A New Key of Understanding for the Health Effects of Curcumin · 2020
No notice
Migraine and Diet · 2020
No notice
Combinatorial Epigenetics Impact of Polyphenols and Phytochemicals in Cancer Prevention and Therapy · 2019
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.